产品介绍
Product Description
PRINCIPLE OF THE ASSAY
This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human ACVR2A has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Bimagrumab in the sample competitively binds to the pre-coated protein with biotin-labeled Bimagrumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Bimagrumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
技术参数
Specifications
| Stability and Storage | When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃. |
| Detection method | Colorimetric |
| Sample type | Plasma, Serum |
| Assay type | Quantitative |
| Sensitivity | 97.28 ng/mL |
| Range | 125 - 4,000 ng/mL |
| Recovery | 80-120% |
| Background | Bimagrumab is a monoclonal anti-ActRIIA/IIB antibody that targets ActRIIA and ActRIIB simultaneously. Native ActRIIA and ActRIIB are both mediators of signaling from several TGFβ superfamily members such as activins, myostatin, and GDF11. Hence, pan-blockade by Bimagrumab achieves greater effect than a monoclonal antibody against either receptor alone, i.e. monotherapy with anti-ActRIIA antibody or anti-ActRIIB antibody. Bimagrumab has been explored as a therapy for sporadic inclusion body myositis, primary sarcopenia, and muscle wasting associated with chronic obstructive pulmonary disease. |
| Alternative Names | BYM338, CAS: 1356922-05-8 |
| Shipping | 2-8 ℃ |
| Specifications | Bimagrumab |
| Note | For Research Use Only. |
